Glaukos Corp
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathw… Read more
Market Cap & Net Worth: Glaukos Corp (GKOS)
Glaukos Corp (NYSE:GKOS) has a market capitalization of $5.91 Billion ($5.91 Billion) as of March 19, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #2535 globally and #1776 in its home market, demonstrating a -2.69% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Glaukos Corp's stock price $102.93 by its total outstanding shares 57434740 (57.43 Million).
Glaukos Corp Market Cap History: 2015 to 2026
Glaukos Corp's market capitalization history from 2015 to 2026. Data shows growth from $1.42 Billion to $5.91 Billion (15.47% CAGR).
Index Memberships
Glaukos Corp is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
S&P Small-Cap 600 Index
SML
|
$1.36 Trillion | 0.43% | #39 of 602 |
Weight: Glaukos Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Glaukos Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Glaukos Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
22.46x
Glaukos Corp's market cap is 22.46 times its annual revenue
0.67x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.42 Billion | $71.70 Million | -$37.24 Million | 19.78x | N/A |
| 2016 | $1.97 Billion | $114.40 Million | $4.52 Million | 17.22x | 435.65x |
| 2017 | $1.47 Billion | $159.25 Million | -$92.00K | 9.25x | N/A |
| 2018 | $3.23 Billion | $181.28 Million | -$12.95 Million | 17.80x | N/A |
| 2019 | $3.13 Billion | $236.98 Million | $15.42 Million | 13.20x | 202.83x |
| 2020 | $4.32 Billion | $224.96 Million | -$120.35 Million | 19.21x | N/A |
| 2021 | $2.55 Billion | $294.01 Million | -$49.59 Million | 8.68x | N/A |
| 2022 | $2.51 Billion | $282.86 Million | -$99.19 Million | 8.87x | N/A |
| 2023 | $4.57 Billion | $314.71 Million | -$134.66 Million | 14.51x | N/A |
| 2024 | $8.61 Billion | $383.48 Million | -$146.37 Million | 22.46x | N/A |
Competitor Companies of GKOS by Market Capitalization
Companies near Glaukos Corp in the global market cap rankings as of March 19, 2026.
Key companies related to Glaukos Corp by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #78 globally with a market cap of $191.37 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #154 globally with a market cap of $121.03 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #168 globally with a market cap of $113.17 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #185 globally with a market cap of $105.26 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #78 | Abbott Laboratories | NYSE:ABT | $191.37 Billion | $110.71 |
| #154 | Stryker Corporation | NYSE:SYK | $121.03 Billion | $349.11 |
| #168 | Medtronic PLC | NYSE:MDT | $113.17 Billion | $88.44 |
| #185 | Boston Scientific Corp | NYSE:BSX | $105.26 Billion | $71.20 |
Glaukos Corp Historical Marketcap From 2015 to 2026
Between 2015 and today, Glaukos Corp's market cap moved from $1.42 Billion to $ 5.91 Billion, with a yearly change of 15.47%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $5.91 Billion | -8.84% |
| 2025 | $6.48 Billion | -24.70% |
| 2024 | $8.61 Billion | +88.63% |
| 2023 | $4.57 Billion | +81.98% |
| 2022 | $2.51 Billion | -1.71% |
| 2021 | $2.55 Billion | -40.95% |
| 2020 | $4.32 Billion | +38.17% |
| 2019 | $3.13 Billion | -3.03% |
| 2018 | $3.23 Billion | +118.99% |
| 2017 | $1.47 Billion | -25.22% |
| 2016 | $1.97 Billion | +38.92% |
| 2015 | $1.42 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Glaukos Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.91 Billion USD |
| MoneyControl | $5.91 Billion USD |
| MarketWatch | $5.91 Billion USD |
| marketcap.company | $5.91 Billion USD |
| Reuters | $5.91 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.